Recruiting

Lovenox with Aspirin

Sponsor:

Fertility Center of Las Vegas

Code:

NCT06133803

Conditions

Infertility, Female

Eligibility Criteria

Sex: Female

Age: 18 - 42

Healthy Volunteers: Accepted

Interventions

Lovenox

Aspirin

Embryo transfer

Study Details

Brief summary:

This prospective randomized trial will compare outcomes in patients receiving aspirin in combination with a low-molecular weight heparin and those under this center's standard protocol receiving neither medication, in order to determine if these medications may improve success rates.

Conditions

Infertility, Female

Study ID

NCT06133803

Start date

Jan 26, 2024

Status verified date

Nov, 2023

Completion date

Dec 15, 2024

Anticipated

Primary completion date

Dec 15, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 42

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Female patient 18-42 years of age with frozen embryos or oocytes seeking embryo transfer.
2. Use of pre-implantation genetically tested (PGT) blastocysts is allowed but not required.
3. Use of donated embryos or embryos derived from donated eggs is allowed.
4. Prior history of successful, failed, and/or canceled IVF cycles are allowed.

Exclusion Criteria:

1. Minor (age<18 years).
2. Currently pregnant.
3. Unable to provide informed consent in English.
4. Gestational carrier or "surrogate".
5. Blastocysts frozen at another center (Oocytes frozen elsewhere is acceptable).
6. Subject intending or having "natural cycle" thaw transfer with an active ovarian follicle present.
7. Currently participating in any other research study.
8. Subject already had an embryo transfer under this study.
9. History of thrombocytopenia (reduced platelets), bleeding disorders, or routinely using anti-coagulant medication.
10. Hypersensitivity to aspirin, heparin, or benzyl alcohol.
11. Anyone for whom the physician assesses this protocol is inappropriate or unsafe.

Study Design

Enrollment

130 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment Arm

Patients randomized to receive aspirin and Lovenox will begin taking one "low dose" 81mg aspirin and one 40mg injection of Lovenox daily, on the day of progesterone start.

active comparator: Control Arm

This arm receives neither medication.

Interventions

Lovenox

A low-molecular-weight heparin, 40mg daily injection.

Aspirin

Aspirin 81mg daily tablet.

Embryo transfer

Embryo transfer

Primary outcome measure

  • Serum hCG level [ Time Frame: 5 days post transfer ]

Central Contacts and Locations

Central contacts

Locations

Fertility center of Las Vegas

Recruiting

Las Vegas, Nevada, United States, 89117

Contacts

More Information

Sponsor

Fertility Center of Las Vegas

Last update posted

Feb 21, 2024

Last verified

Nov, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Fertility Center of Las Vegas on 2024-02-21.